Boehringer Ingelheim has decided to discontinue development of flibanserin, its compound for hypoactive sexual desire disorder in pre-menopausal women, following its rejection by the US Food and Drug Administration. ---Subscribe to MedNous to access this article--- Regulation & Policy Company News
